Zynex (NASDAQ:ZYXI) Issues Q4 2024 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its fourth quarter 2024 earnings guidance on Thursday. The company provided EPS guidance of 0.090- for the period, compared to the consensus EPS estimate of 0.100. The company issued revenue guidance of $53.6 million-, compared to the consensus revenue estimate of $53.3 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.

Zynex Stock Up 6.2 %

Shares of Zynex stock traded up $0.53 during midday trading on Friday, hitting $9.12. The company had a trading volume of 264,477 shares, compared to its average volume of 173,892. Zynex has a 52-week low of $7.04 and a 52-week high of $13.77. The company has a debt-to-equity ratio of 1.79, a quick ratio of 3.22 and a current ratio of 4.06. The stock has a market capitalization of $289.79 million, a P/E ratio of 39.65 and a beta of 0.54. The company has a 50 day moving average of $8.01 and a 200 day moving average of $9.18.

Zynex (NASDAQ:ZYXI) last released its earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Zynex had a return on equity of 14.15% and a net margin of 3.12%. The firm had revenue of $49.97 million for the quarter, compared to analysts’ expectations of $50.83 million. During the same period in the prior year, the firm posted $0.10 earnings per share. The company’s quarterly revenue was up .1% on a year-over-year basis. On average, equities analysts predict that Zynex will post 0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ZYXI has been the subject of several recent analyst reports. Royal Bank of Canada decreased their target price on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. HC Wainwright lifted their target price on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Friday.

Insider Activity

In related news, Director Joshua R. Disbrow bought 7,000 shares of the business’s stock in a transaction on Monday, July 29th. The stock was acquired at an average price of $8.32 per share, with a total value of $58,240.00. Following the transaction, the director now owns 72,000 shares in the company, valued at approximately $599,040. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In related news, COO Anna Lucsok sold 8,083 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total value of $64,906.49. Following the transaction, the chief operating officer now owns 16,980 shares of the company’s stock, valued at approximately $136,349.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Joshua R. Disbrow bought 7,000 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The shares were acquired at an average price of $8.32 per share, with a total value of $58,240.00. Following the completion of the transaction, the director now directly owns 72,000 shares of the company’s stock, valued at $599,040. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 52.13% of the stock is owned by corporate insiders.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.